Navigation Links
Mylan Announces Proposed Add-On Private Placement of its Senior Notes Due 2020
Date:7/29/2010

requirements. This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, any securities, nor shall there be any sale of securities mentioned in this press release in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 140 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information, please visit www.mylan.com.

Forward-Looking Statements

This press release includes statements that constitute "forward-looking statements." These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to Mylan's failure to consummate the proposed private placement or to utilize the proceeds of such placement as described in this press release. These cautionary statements should be considered in connection with any subsequent written or oral forward-looking statements that may be made by Mylan or
'/>"/>

SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Mark W. Parrish Joins Mylans Board of Directors
2. WHO Withdraws Notice of Concern for Mylans Matrix Unit
3. Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009
4. Mylan Receives FDA Approval for Generic Version of Prostate Cancer Treatment Casodex(R)
5. Mylan Announces Strategic Collaboration with Biocon to Enter the Global Generic Biologics Market
6. Mylan Again Calls for an End to Authorized Generics During 180-Day Exclusivity Period
7. Mylan Receives Tentative FDA Approval for Generic Version of Singulair(R)
8. Mylans Matrix Selected by the Clinton HIV/AIDS Initiative and UNITAID as the Primary Supplier of Five Second-Line and Seven Pediatric HIV/AIDS Treatments
9. Mylans Matrix Receives First Tentative FDA Approval Under PEPFAR for Generic Truvada(R)
10. Mylan Confirms Four First-to-File Challenges
11. Shire Files Lawsuit Against Mylan for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... has sepsis, a life-threatening condition in which bacteria or ... fast for antibiotics to help. A new device inspired ... at Harvard,s Wyss Institute for Biologically Inspired Engineering may ... "Even with the best current treatments, sepsis patients are ... of the time," said Mike Super, Ph.D., Senior Staff ...
(Date:9/15/2014)... September 15, 2014 Bioptigen ... imaging OCT system for the optical device metrology and ... EnvisuTM S4410 SDOCT for Contact Lens Metrology is ... and high complexity contact lens, IOL structures, and donor ... a complete contact lens immersed in a hydration bath ...
(Date:9/15/2014)... Sept. 15, 2014 Research and Markets ... Market by Product, by Services, by Technology, by Application - ... Whole Exome Sequencing (WES) is next-generation technology used ... the exon. The exome, which is the total of all ... genome and is actually converted into proteins after translation. It ...
(Date:9/15/2014)... Die zweite jährliche International Plasma ... 18. Oktober stattfinden. Die IPAW ist eine gemeinsame ... (PPTA) und ihrer Mitgliedsunternehmen und hat ... für die Gewinnung von Quellplasma zu steigern ... Verbessern von Leben zu würdigen , Das ...
Breaking Biology Technology:Blood-cleansing biospleen device developed for sepsis therapy 2Blood-cleansing biospleen device developed for sepsis therapy 3Blood-cleansing biospleen device developed for sepsis therapy 4Bioptigen Introduces Deep Imaging OCT System for Contact Lens Metrology 2Global Whole Exome Sequencing (Systems, Kits, Library Preparation, Target Enrichment) Market by Product, by Services, by Technology, by Application - Forecast to 2018 2Global Whole Exome Sequencing (Systems, Kits, Library Preparation, Target Enrichment) Market by Product, by Services, by Technology, by Application - Forecast to 2018 3International Plasma Awareness Week feiert Spender und rückt seltene Krankheiten in den Mittelpunkt 2International Plasma Awareness Week feiert Spender und rückt seltene Krankheiten in den Mittelpunkt 3
... , , , FORT ... Board: OMCM), a leader in integrated electronic data capture (EDC) ... selected by a leading European based Contract Research Organization (CRO) ... in rheumatoid arthritis (RA). Phase III clinical studies serve to ...
... ANNAPOLIS, Md., Aug. 13 PharmAthene, Inc. (NYSE Amex: ... chemical threats, today reported financial and operational results for the second ... For the second quarter of 2009, PharmAthene recognized revenues ... of 2008. For the six months ended June 30, 2009 ...
... China, Aug. 13 /PRNewswire-Asia-FirstCall/ -- Tianyin,Pharmaceutical Co., Inc., (NYSE ... of,modernized traditional Chinese medicine ("TCM") based in Chengdu, China, ... State Food and Drug,Administration (SFDA) to produce Sanqi Tablets ... and Yinqiao Jiedu Tablets in,dosage form of 0.5 gram/tablet ...
Cached Biology Technology:Leading European Contract Research Organization Selects OmniComm to Provide eClinical Solutions for Important Phase III Study 2PharmAthene Reports Second Quarter 2009 Financial and Operational Results 2PharmAthene Reports Second Quarter 2009 Financial and Operational Results 3PharmAthene Reports Second Quarter 2009 Financial and Operational Results 4PharmAthene Reports Second Quarter 2009 Financial and Operational Results 5PharmAthene Reports Second Quarter 2009 Financial and Operational Results 6PharmAthene Reports Second Quarter 2009 Financial and Operational Results 7PharmAthene Reports Second Quarter 2009 Financial and Operational Results 8Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Sanqi Tablets and Yinqiao Jiedu Tablets 2Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Sanqi Tablets and Yinqiao Jiedu Tablets 3
(Date:9/15/2014)... that reef biodiversity may not provide the level of ... In an international study published today, Professor David Bellwood ... Studies (Coral CoE) says we need to identify and ... In coral reefs, just as in any modern-day society, ... and functioning. , Professor Bellwood says, in many ...
(Date:9/15/2014)... million years after it formed may have been surprisingly ... and active crustal plates. , This alternate view of ... substantial new support from the first detailed comparison of ... ago with those formed contemporaneously in Iceland, which has ... Earth. , The study was conducted by a team ...
(Date:9/15/2014)... who transplanted combinations of wild, domesticated, and ... to new environments found that within 5 ... foreign genes from wild populations that hybridized ... Applications study provides evidence that natural ... that hybridized populations experience as a result ...
Breaking Biology News(10 mins):Specialized species critical for reefs 2Early Earth less hellish than previously thought 2Early Earth less hellish than previously thought 3
... Australian scientists have found that the bacterium Cupriavidus ... toxic gold compounds to their metallic form using active ... on gold surfaces but have never clearly elucidated their ... that there may be a biological reason for the ...
... . , Leishmania is a deadly parasitic disease ... million new cases reported every year. Until recently, scientists were unsure ... now been solved according to a new study published in ... a scientist at the Research Institute of the McGill University ...
... Communication Intelligence Corporation ("CIC") (OTC Bulletin Board: ... for business process automation in the financial industry* ... announced today that a top-three U.S. bank will ... rollout including several thousand recently acquired branches. , ...
Cached Biology News:Bacterium helps formation of gold 2Major discovery opens door to leishmania treatment 2Top-Three US Bank Chooses CIC Electronic Signature Technology for Branch-Wide Deployment 2Top-Three US Bank Chooses CIC Electronic Signature Technology for Branch-Wide Deployment 3
...
CREB-2 (H-290)...
Immunogen: Recombinant full length protein, corresponding to amino acids 1-435 of Human AP2M1. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Anti-Dynamin Monoclonal Antibody Description: 100 g Research Focus: neuroscience Storage: -20C Shipping Temperature: 4C...
Biology Products: